


1625/22W  
Jm

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: S. DEBENHAM et al.



Serial No. 10/576,796

Filed: April 21, 2006

For: SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES

Art Unit: \_\_\_\_\_

Examiner: \_\_\_\_\_

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK &amp; CO., INC.

By

Date

6/22/2006

**INFORMATION DISCLOSURE STATEMENT**

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: CATHERINE D. FITCH

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 36,502

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4283

Date: June 22, 2006

## INFORMATION DISCLOSURE

JUN 26 2006

(use as many sheets as necessary)

Sheet

1

of

3

**COMPLETE IF KNOWN**

Application Number

10/576.796

**Filing Date**

April 21, 2006

**First Named Inventor**

J.S. Debenham et al.

### Group Art Unit

—

Examiner Name

Attorney Docket Number

21176YP

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
RD			WO 2004/087704		AstraZeneca AB	10/14/2004
RD			WO 99/02499		Japan Tobacco Inc.	01/21/1999
RD			WO 2005/021547		Pharmaxis Pty Ltd.	03/10/2005
RD			WO 2005/061504		Pfizer Products Inc.	07/07/2005
RD			WO 2005/061507		Pfizer Products Inc.	07/07/2005
RD			WO 2005/061505		Pfizer Products Inc.	07/07/2005
RD			WO 2005/049615		Pfizer Products Inc.	06/02/2005
RD			WO 2005/035532		Pfizer Products Inc.	04/21/2005
RD			WO 2005/103052		Pfizer Products Inc.	01/03/2005
RD			WO 2004/060882		AstraZeneca AB	07/22/2004

/RITA DESAI/

6/03/09

**SEND TO:** Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS'Form" (IDS Folder), Merck & Co., Inc., -7/12/2005



Substitute for form 1449B/PTO

### STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/576,796
<b>Filing Date</b>	April 21, 2006
<b>First Named Inventor</b>	J.S. Debenham et al.
Group Art Unit	--
Examiner Name	
<b>Attorney Docket Number</b>	21176YP

## NON PATENT LITERATURE DOCUMENTS

Examiner  
Initials\*Cite  
No.

**Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.**

RD

AA

Ferrarini et al., *Bioorg. & Medicinal Chem.*, Vol. 12 (2004), pp. 1921-1933, "Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors"

RD

AB

Lange et al., *Current Opin. in Drug Discovery & Develop.*, Vol. 7 (2004), pp. 498-506, "Recent advances in CB1 cannabinoid receptor antagonists"

RD

AC

Pertwee, Exp. Opin. Invest. Drugs, Vol., 9 (2000), pp. 1553-1571, "Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development"

RD

LAD

Pertwee, *Addiction Biology*, Vol. 5 (2000), pp. 37-46, "Neuropharmacology and therapeutic potential of cannabinoids"

RD

AE

Evens et al., American Chem. Society, Vol. 12 (1979), "Poly(1,8-naphthyridines) and 1,9,10-anthyridines: Model systems for "Black Orlon"

Examiner  
Signature

/RITA DESAI/

Date  
Considered

6/03/09

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005